Literature DB >> 9275213

The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1.

S F Lacey1, C B McDanal, R Horuk, M L Greenberg.   

Abstract

Primary CD8+ T cells from HIV+ asymptomatics can suppress virus production from CD4(+) T cells acutely infected with either non-syncytia-inducing (NSI) or syncytia-inducing (SI) HIV-1 isolates. NSI strains of HIV-1 predominantly use the CCR5 chemokine receptor as a fusion cofactor, whereas fusion of T cell line-adapted SI isolates is mediated by another chemokine receptor, CXCR4. The CCR5 ligands RANTES (regulated on activation, normal T cell expressed and secreted), macrophage inflammatory protein 1alpha (MIP-1alpha), and MIP-1beta are HIV-1 suppressive factors secreted by CD8+ cells that inhibit NSI viruses. Recently, the CXC chemokine stromal cell-derived factor 1 (SDF-1) was identified as a ligand for CXCR4 and shown to inhibit SI strains. We speculated that SDF-1 might be an effector molecule for CD8+ suppression of SI isolates and assessed several SDF-1 preparations for inhibition of HIV-1LAI-mediated cell-cell fusion, and examined levels of SDF-1 transcripts in CD8(+) T cells. SDF-1 fusion inhibitory activity correlated with the N terminus, and the alpha and beta forms of SDF-1 exhibited equivalent fusion blocking activity. SDF-1 preparations having the N terminus described by Bleul et al. (Bleul, C.C., Fuhlbrigge, R.C., Casasnovas, J.M., Aiuti, A. & Springer, T.A. (1996) J. Exp. Med. 184, 1101-1109) readily blocked HIV-1LAI-mediated fusion, whereas forms containing two or three additional N-terminal amino acids lacked this activity despite their ability to bind and/or signal through CXCR4. Though SDF-1 is constitutively expressed in most tissues, CD8 T cells contained extremely low levels of SDF-1 mRNA transcripts (<1 transcript/5,000 cells), and these levels did not correlate with virus suppressive activity. We conclude that suppression of SI strains of HIV-1 by CD8+ T cells is unlikely to involve SDF-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9275213      PMCID: PMC23279          DOI: 10.1073/pnas.94.18.9842

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

2.  Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

Authors:  M Tersmette; J M Lange; R E de Goede; F de Wolf; J K Eeftink-Schattenkerk; P T Schellekens; R A Coutinho; J G Huisman; J Goudsmit; F Miedema
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

3.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.

Authors:  M Loetscher; T Geiser; T O'Reilly; R Zwahlen; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

5.  Interleukin-8 antagonists generated by N-terminal modification.

Authors:  B Moser; B Dewald; L Barella; C Schumacher; M Baggiolini; I Clark-Lewis
Journal:  J Biol Chem       Date:  1993-04-05       Impact factor: 5.157

Review 6.  Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.

Authors:  S M Schnittman; A S Fauci
Journal:  Adv Intern Med       Date:  1994

7.  CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

Authors:  C H Chen; K J Weinhold; J A Bartlett; D P Bolognesi; M L Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

8.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.

Authors:  C M Walker; J A Levy
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities.

Authors:  I Clark-Lewis; C Schumacher; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

View more
  9 in total

1.  Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.

Authors:  F Cocchi; A L DeVico; R Yarchoan; R Redfield; F Cleghorn; W A Blattner; A Garzino-Demo; S Colombini-Hatch; D Margolis; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage.

Authors:  Kevin O Saunders; Cavin Ward-Caviness; Robert J Schutte; Stephanie A Freel; R Glenn Overman; Nathan M Thielman; Coleen K Cunningham; Thomas B Kepler; Georgia D Tomaras
Journal:  Cell Immunol       Date:  2010-10-27       Impact factor: 4.868

Review 3.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 4.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

5.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

Authors:  R Geiben-Lynn; M Kursar; N V Brown; E L Kerr; A D Luster; B D Walker
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

Authors:  A Trkola; W A Paxton; S P Monard; J A Hoxie; M A Siani; D A Thompson; L Wu; C R Mackay; R Horuk; J P Moore
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Functional characterization of human Tc0, Tc1 and Tc2 CD8+ T cell clones: control of X4 and R5 HIV strain replication.

Authors:  Michèle Février; Sylvie le Borgne; Christian Marty; Antoine Talarmin; Yves Rivière
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

9.  CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.

Authors:  G D Tomaras; S F Lacey; C B McDanal; G Ferrari; K J Weinhold; M L Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.